Titan Pharmaceuticals (NASDAQ:TTNP) appointed Dane Hallberg to the newly created position of EVP and chief commercial officer, effective immediately, with responsibility for leading all of the company’s commercial...
Health Canada has approved the sale of Probuphine, a subdermal implant developed by Titan Pharmaceuticals (NASDAQ:TTNP), for the management of opioid dependence in patients clinically stabilized on no more than 8 mg of...
Titan Pharmaceuticals (NASDAQ:TTNP) has entered into a definitive asset purchase, supply and support agreement with closely-held L. Molteni & C. dei F.lli Alitti Società di Esercizio S.p.A. of Italy, through which...